Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 6c, Revenues Miss
May 3, 2021 7:07 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.77), $0.06 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $23.26 million versus the consensus estimate of $25.75 million.
"We are encouraged to see patient demand for XPOVIO return to growth in the first quarter of 2021, and we remain confident in its long-term commercial potential and our ability to further increase utilization and... More
